NEW YORK, May 27 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) today listed the common stock of Rexahn Pharmaceuticals, Inc. under the ticker symbol RNN.
Rexahn Pharmaceuticals is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy.
"We are pleased to welcome Rexahn Pharmaceuticals to the American Stock Exchange," said Neal Wolkoff, Chairman and CEO, of the Amex. "We look forward to working with Rexahn in building increased awareness and visibility within the investment community."
"As we continue to aggressively pursue our clinical development efforts, our listing on the Amex will increase shareholder value and provide expanded visibility to the investment community and capital markets, at large," stated Dr. Chang H. Ahn, Chairman and Chief Executive Officer of Rexahn.
The specialist for Rexahn Pharmaceuticals, Inc. is AGS Specialist Partners. For further information on RNN and other Amex-listed companies, please visit http://www.amex.com.
About American Stock Exchange
The American Stock Exchange(R) (Amex(R)) offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 401 ETFs to date. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks. For more information, please visit http://www.amex.com.
|SOURCE American Stock Exchange|
Copyright©2008 PR Newswire.
All rights reserved